-logo.jpg "Veru logo")
Veru Inc. operates as a urology and oncology biopharmaceutical company. The company operates through two segments, Commercial; and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which are under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil-Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate; VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-722 that is in Phase II clinical trial for the treatment of male infertility caused by testicular dysfunction. The company's oncology drug candidate is VERU-111, a novel oral alpha and beta tubulin inhibitor, which is under preclinical study for the treatment of metastatic prostate, breast, endometrial, ovarian, and other cancers. It also develops VERU-111/VERU-112, a novel oral agent targeting colchicine binding site that is under preclinical study for the treatment of gout and familial mediterranean fever. Veru Inc. serves agencies, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Industry, Sector and Symbol
Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897
Debt
Debt-to-Equity Ratio0.14
Current Ratio1.53
Quick Ratio1.19
Price-To-Earnings
Trailing P/E Ratio-8.96
Forward P/E Ratio-12.50
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.66 million
Price / Sales8.81
Cash FlowN/A
Price / CashN/A
Book Value$0.91 per share
Price / Book2.47
Profitability
EPS (Most Recent Fiscal Year)($0.25)
Net Income$-6,610,000.00
Net Margins-87.78%
Return on Equity-21.72%
Return on Assets-16.38%
Miscellaneous
Employees175
Outstanding Shares53,510,000
Veru (NASDAQ:VERU) Frequently Asked Questions
What is Veru's stock symbol?
Veru trades on the NASDAQ under the ticker symbol "VERU."
How were Veru's earnings last quarter?
Veru Inc (NASDAQ:VERU) announced its earnings results on Wednesday, May, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.02. The company had revenue of $2.57 million for the quarter, compared to the consensus estimate of $7.60 million. Veru had a negative return on equity of 21.72% and a negative net margin of 87.78%. View Veru's Earnings History.
When is Veru's next earnings date?
What price target have analysts set for VERU?
2 brokerages have issued twelve-month target prices for Veru's shares. Their predictions range from $5.00 to $5.00. On average, they expect Veru's share price to reach $5.00 in the next year. View Analyst Ratings for Veru.
Who are some of Veru's key competitors?
Some companies that are related to Veru include Zealand Pharma Aktieselskabet (ZLDPF), Computer Programs & Systems (CPSI), Starpharma (SPL), Concert Pharmaceuticals (CNCE), Depomed (DEPO), Unum Therapeutics (UMRX), Virtus Health (VRT), Weed (BUDZ), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), Nightstar Therapeutics (NITE), ArQule (ARQL), Dermira (DERM), Sinovac Biotech (SVA) and Antares Pharma (ATRS).
Who are Veru's key executives?
Veru's management team includes the folowing people:
- Mr. O. B. Parrish, Co-Founder & Vice Chairman (Age 85)
- Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 59)
- Dr. Harry Fisch, Chief Corp. Officer & Director (Age 59)
- Dr. Mitchell S. Steiner, Pres, CEO & Director (Age 57)
- Mr. Kevin J. Gilbert, Sr. VP of Corp. Devel. & Legal and Sec.
Has Veru been receiving favorable news coverage?
Press coverage about VERU stock has trended somewhat positive recently, Accern reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Veru earned a daily sentiment score of 0.11 on Accern's scale. They also assigned news coverage about the company an impact score of 48.19 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Veru?
Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veru's stock price today?
One share of VERU stock can currently be purchased for approximately $2.25.
How big of a company is Veru?
Veru has a market capitalization of $118.80 million and generates $13.66 million in revenue each year. The company earns $-6,610,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Veru employs 175 workers across the globe.
How can I contact Veru?
Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]
MarketBeat Community Rating for Veru (VERU)
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
